Cardiff OncologyCRDF 53 Market Cap is $82.73 Mil as of Jun. 26, 2026. GuruFocus rates CRDF with a GF Score™ of 53/100 and a GF Value™ of $1.48 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,431 Biotechnology companies, Cardiff Oncology ranks worse than 55.14% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cardiff Oncology's share price for the quarter that ended in Mar. 2026 was $1.62. Cardiff Oncology's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 68.37 Mil. Therefore, Cardiff Oncology's market cap for the quarter that ended in Mar. 2026 was $110.76 Mil.
Cardiff Oncology's quarterly market cap
increased
from Sep. 2025 ($138.22 Mil) to Dec. 2025 ($191.94 Mil) but then
declined
from Dec. 2025 ($191.94 Mil) to Mar. 2026 ($110.76 Mil).
Cardiff Oncology's annual market cap
increased
from Dec. 2023 ($66.12 Mil) to Dec. 2024 ($288.71 Mil) but then
declined
from Dec. 2024 ($288.71 Mil) to Dec. 2025 ($191.94 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cardiff Oncology's Enterprise Value for Today is $37.32 Mil.
Cardiff Oncology (NAS:CRDF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cardiff Oncology Market Cap Related Terms
Cardiff Oncology Market Cap Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardiff Oncology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Market Cap distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cardiff Oncology's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (CRDF) has a Market Cap of $82.73 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cardiff Oncology and its competitors. According to the industry distribution chart, Cardiff Oncology ranks #789 out of 1431 companies in the Biotechnology industry, placing it in the top 55.1%.
Is Cardiff Oncology's Market Cap too high?
Cardiff Oncology's current Market Cap is $82.73 Mil. The Biotechnology industry median Market Cap is 113.83. Cardiff Oncology's value of $82.73 Mil is 27.3% below this industry median. Based on the distribution chart, Cardiff Oncology ranks #789 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cardiff Oncology has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Market Cap compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #789 out of 1431 companies for Market Cap. This places Cardiff Oncology in the lower half of its industry. The industry median Market Cap is 113.83. Cardiff Oncology's value of $82.73 Mil is 27.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Oncology's current Market Cap of $82.73 Mil is 27.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cardiff Oncology and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current Market Cap is $82.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.48, compared to a current price of $1.21 — trading 18.2% below its estimated fair value. The current Market Cap is $82.73 Mil and 27.3% below the Biotechnology industry median of 113.83. Cardiff Oncology's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Market Cap is $82.73 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Oncology (CRDF) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued.
The current stock price of $1.21 is trading 18.2% below its estimated GF Value™ of $1.48.
GuruFocus considers Cardiff Oncology to be Modestly Undervalued.
Key valuation signals for CRDF:
Market Cap: $82.73 Mil
GF Value™: $1.48 vs. price of $1.21 (18.2% below fair value)
Industry Position: 27.3% below the Biotechnology median (#789 of 1431)
No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
53GF Score
Get the complete analysis for CRDF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
